T. Goda

Late Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor

Y. Nagashima, I. Kinoshita, J. Taguchi, 2018, Internal medicine.

Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck

M. Takahara, H. Dosaka-akita, A. Homma, 2020, International Journal of Clinical Oncology.

Leiomyosarcoma arising from the ovarian vein as a gynecologic malignancy: Two case reports and a review of the literature

Y. Yokoyama, Tomoko Kanda, Yasumasa Sato, 2022, The journal of obstetrics and gynaecology research.

[Black esophagus due to acute necrotizing esophagitis: four case reports].

J. Fujita, Y. Ishibashi, J. Suzuki, 2011, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

A case of gliomatosis peritonei detected using diagnostic laparoscopy for an intrapelvic tumor after surgery for an ovarian immature teratoma (grade 1)

Y. Yokoyama, Tomoko Kanda, T. Goda, 2022, JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY.

Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).

H. Dosaka-akita, F. Hommura, T. Harada, 2021, Lung cancer.

A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial.

H. Dosaka-akita, T. Harada, S. Oizumi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

H. Dosaka-akita, F. Hommura, T. Harada, 2023, Cancer medicine.

Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study

H. Dosaka-akita, K. Hirata, Keiichi Magota, 2023, EJNMMI Research.